ntr.oxfordjournals.org Funding This work was supported by the NCI at the National Institutes of Health (sponsor award number HHSN261200900395P) Ruxolitinib CAS awarded to JNS. Declaration of Interests None declared. Supplementary Material Supplementary Data: Click here to view. Acknowledgments The authors would like to thank the Deputy Editor and both reviewers for their valuable feedback that helped improve the manuscript, senior program analyst James Gibson for providing the data set and science writer Anne Brown Rodgers for her editorial suggestions.
Eight EC users (3 women; 8 Caucasian) consented to and completed this single-session (5 hr) Institutional Review Board-approved protocol. Participants used their own fully charged EC, and a prefilled cartomizer (heater + liquid) of their chosen flavor/nicotine content was provided.
At the start of the session, participants were surveyed regarding health, demographics, and EC use habits. Participants were included in the study if they reported using an EC for at least 3 months, used at least 2�C3 ml of nicotine solution or two cartridges per day, used nicotine solution of at least 10 mg/ml nicotine, smoked fewer than five cigarettes per day, and were between the ages of 18 and 55. Participants were excluded if they reported any chronic health or psychiatric conditions, had a history of high or low blood pressure, or were unwilling to use a cartridge or cartomizer during the session. Participants were required to abstain from all nicotine and tobacco product use, including ECs, for at least 12 hr prior to the session.
Abstinence was verified upon arrival at the laboratory by a carbon monoxide level of 10 ppm or less and was further verified later by plasma nicotine levels at or below the limit of quantification (2 ng/ml). At session onset, a venous catheter was inserted into the participant��s forearm vein and continuous physiological monitoring commenced. Approximately 55 min later, blood was sampled, and 5 min after that, participants were provided with their EC and were instructed to take 10 puffs (30-s interpuff interval [IPI; as in Eissenberg, 2010; Vansickel et al., 2010]). Blood was sampled 5 and 15 min after the start of the 10-puff period. Then, a 60-min ad lib puffing period began, and blood was sampled every 15 min. Participants then entered a 2-hr rest period during which no puffing occurred, and blood was sampled every 30 min.
Participants completed subjective questionnaires at baseline and again after the 10-puff, ad lib, and rest periods. At session��s end, the venous catheter was removed, physiological monitoring ceased, and participants were compensated. Physiological outcome measures included heart rate (measured every Entinostat 20 s) and plasma nicotine concentration (blood centrifuged and plasma stored at ?70 ��C for analysis of nicotine concentration).